Chemotherapy using gemcitabine and docetaxel for advanced bone and soft tissue sarcoma

Chemotherapy using gemcitabine and docetaxel for advanced bone and soft tissue sarcoma - Chemotherapy using gemcitabine and docetaxel for advanced bone and soft tissue sarcoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021202

Enrollment

Registered

2016-02-26

Start date

2014-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced bone and soft tissue tumor

Interventions

Gemcitabine(675mg/m2 day1,8) + Docetaxel(75mg/m2 day8) 1course/3weeks 4 courses

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Recurrent, metastatic or unresectable bone and soft tissue sarcoma 2)Patients who had been previously treated with first-line chemotherapy 3)ECOG Performance Status Scale(PS):0-2 4)Patients who had adequate hematologic, renal, and hepatic function 5)After obtaining informed consent

Exclusion criteria

Exclusion criteria: 1) Past history of allegy for gemcitabine or docetaxel 2) Interstitial pneumonitis or pulmonary fibrosis 3) Active infection 4) Pregnancy 5) Lactation 6) Double cancer

Design outcomes

Primary

Measure	Time frame
progression-free survival	—

Secondary

Measure	Time frame
adverse effect	—

Countries

Japan

Contacts

Public ContactHiroaki Kimura

Nagoya City University, Graduate School of Medical Science Department of Orthpaedic Surgery

hiroaki030301@yahoo.co.jp052-835-8236

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026